On December 19, Glodon Finance reported that Luyan Pharma (002788.SZ) recently stated during a meeting with institutional investors that the company is building a new development pattern of 'one platform + two driving forces.' Using Luyan's big health business as a platform, it continuously creates value and constantly strengthens, enlarges, and optimizes its endeavors; with the modernization of Traditional Chinese Medicine and the new technology industry as the two driving forces, it aims to create the Luyan big health ecosystem and establish a new frontier for Luyan's business development.
Great efforts are being made to advance the construction of the Bozhou modern Traditional Chinese Medicine production project, which started construction in February 2022. The first phase was capped in March this year, and it is currently undergoing renovations and installing equipment. At the same time, the company is actively exploring and developing the application of AI and Big Data in the medical health service field.
